Ron Put Posted July 21, 2019 Report Share Posted July 21, 2019 From centenarians' genetic code, a potential new therapy against cardiovascular diseasesSome people live much longer than average, partly thanks to their DNA. A study, published in the European Heart Journal, shows that it could be possible to replicate this genetic gift even for those lacking it. The way is now open to an innovative therapy model capable of preventing and fighting cardiovascular diseases through a real rejuvenation of blood vessels. The study, conducted by the I.R.C.C.S. Neuromed, the I.R.C.C.S. Multimedica and the Department of Medicine, Surgery, and Dentistry, Salerno Medical School University of Salerno, with the support of the Cariplo Foundation and the Italian Ministry of Health, focuses on the gene that encodes the BPIFB4 protein. In the past, the same research group had identified a variant of this gene, the so-called LAV ("longevity associated variant"), which prevails in people over 100 years of age. Now, through a viral vector, researchers have inserted the LAV-BPIFB4 gene into the DNA of animal models particularly susceptible to atherosclerosis and, consequently, to cardiovascular diseases. "The results—says Annibale Puca, coordinator of a research team at the University of Salerno and at I.R.C.C. MultiMedica—were extremely encouraging. We observed an improvement in the functionality of the endothelium (the inner surface of blood vessels), a reduction of atherosclerotic plaques in the arteries and a decrease in the inflammatory state."In other words, the inclusion of the "centenarian gene" in animal models has caused a real rejuvenation of the cardiovascular system. The same positive effect was also achieved in the laboratory, this time not by inserting genes, but by delivering the LAV-BPIFB4 protein to human blood vessels.https://medicalxpress.com/news/2019-07-centenarians-genetic-code-potential-therapy.html Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.